Footprint- and xeno-free human iPSCs derived from urine cells using extracellular matrix-based culture conditions

Lee, Kang-In; Kim, Hyeong-Taek; Hwang, Deuk-Soo

doi:10.1016/j.biomaterials.2014.05.059

Cited by 22 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Nakagawa et al [ 38 ] were able to obtain an adequate number of footprint-free, xeno-free hiPSC clones from both skin-derived fibroblasts and blood cells. Lee et al [ 39 ] reported a method to generate footprint- and xeno-free iPSC from urine cells which can be obtained totally noninvasively using extracellular matrix-based xeno-free iPSC culture condition and episomal transfection.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications

Cefalo

Carai

Miele

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

Many central nervous system (CNS) diseases including stroke, spinal cord injury (SCI), and brain tumors are a significant cause of worldwide morbidity/mortality and yet do not have satisfying treatments. Cell-based therapy to restore lost function or to carry new therapeutic genes is a promising new therapeutic approach, particularly after human iPSCs became available. However, efficient generation of footprint-free and xeno-free human iPSC is a prerequisite for their clinical use. In this paper, we will first summarize the current methodology to obtain footprint- and xeno-free human iPSC. We will then review the current iPSC applications in therapeutic approaches for CNS regeneration and their use as vectors to carry proapoptotic genes for brain tumors and review their applications for modelling of neurological diseases and formulating new therapeutic approaches. Available results will be summarized and compared. Finally, we will discuss current limitations precluding iPSC from being used on large scale for clinical applications and provide an overview of future areas of improvement. In conclusion, significant progress has occurred in deriving iPSC suitable for clinical use in the field of neurological diseases. Current efforts to overcome technical challenges, including reducing labour and cost, will hopefully expedite the integration of this technology in the clinical setting.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Various matrices can be used to replace feeder cells, such as Matrigel, CELLstart, recombinant proteins, and synthetic polymers. Xeno-free media recently developed include TeSR2 and Essential E8 medium [ 39 ].…”

Section: Methodsmentioning

confidence: 99%

Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications

Cefalo

Carai

Miele

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…A recent study described episomal derivation of iPSC from novel urine cells as well as adipose tissue-derived stromal cells under xeno-free conditions. 46 Among other tests, the authors utilized PluriTest to determine the degree of pluripotency in the novel iPSC lines, along with the control H9 human embryonic stem cell line, also adapted to the xeno-free conditions. The individual lines clustered in an area similar to that of AF-iPSC described here, including the H9 control line (that exhibited the highest pluripotency score).…”

Section: Discussionmentioning

confidence: 99%

Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions

et al. 2016

View full text Add to dashboard Cite

Amniotic fluid stem cells (AFSC) represent an attractive potential cell source for fetal and pediatric cellbased therapies. However, upgrading them to pluripotency confers refractoriness toward senescence, higher proliferation rate and unlimited differentiation potential. AFSC were observed to rapidly and efficiently reacquire pluripotency which together with their easy recovery makes them an attractive cell source for reprogramming. The reprogramming process as well as the resulting iPSC epigenome could potentially benefit from the unspecialized nature of AFSC. iPSC derived from AFSC also have potential in disease modeling, such as Down syndrome or b-thalassemia. Previous experiments involving AFSC reprogramming have largely relied on integrative vector transgene delivery and undefined serumcontaining, feeder-dependent culture. Here, we describe non-integrative oriP/EBNA-1 episomal plasmidbased reprogramming of AFSC into iPSC and culture in fully chemically defined xeno-free conditions represented by vitronectin coating and E8 medium, a system that we found uniquely suited for this purpose. The derived AF-iPSC lines uniformly expressed a set of pluripotency markers Oct3/4, Nanog, Sox2, SSEA-1, SSEA-4, TRA-1-60, TRA-1-81 in a pattern typical for human primed PSC. Additionally, the cells formed teratomas, and were deemed pluripotent by PluriTest, a global expression microarray-based insilico pluripotency assay. However, we found that the PluriTest scores were borderline, indicating a unique pluripotent signature in the defined condition. In the light of potential future clinical translation of iPSC technology, non-integrating reprogramming and chemically defined culture are more acceptable.

show abstract

“…To overcome the shortcomings of feeder layers, extensive effort has been devoted to the development of feeder‐/xeno‐free systems to expand iPSCs (Celiz et al , ; Lee et al , ). Matrigel ™ has been widely employed as an alternative iPSC expansion substrate to bridge the gap between feeder‐based and defined feeder‐free iPSC expansion (Villa‐Diaz et al , ).…”

Section: Engineered Biomaterials For the Expansion Of Ipscsmentioning

confidence: 99%

“…This chemically defined medium functioned synergistically with the vitronectin coating to induce and maintain iPSCs with high colony‐forming efficiency and pluripotency. A similar vitronectin substrate has been utilized for generating and expanding functional iPSCs from human urine‐derived cells as well (Lee et al , ). These findings reinforce that vitronectin is a robust substrate that can assist the self‐renewal of iPSCs derived from different somatic cell types.…”

Section: Engineered Biomaterials For the Expansion Of Ipscsmentioning

confidence: 99%

Application of biomaterials to advance induced pluripotent stem cell research and therapy

et al. 2015

View full text Add to dashboard Cite

Derived from any somatic cell type and possessing unlimited selfrenewal and differentiation potential, induced pluripotent stem cells (iPSCs) are poised to revolutionize stem cell biology and regenerative medicine research, bringing unprecedented opportunities for treating debilitating human diseases. To overcome the limitations associated with safety, efficiency, and scalability of traditional iPSC derivation, expansion, and differentiation protocols, biomaterials have recently been considered. Beyond addressing these limitations, the integration of biomaterials with existing iPSC culture platforms could offer additional opportunities to better probe the biology and control the behavior of iPSCs or their progeny in vitro and in vivo. Herein, we discuss the impact of biomaterials on the iPSC field, from derivation to tissue regeneration and modeling. Although still exploratory, we envision the emerging combination of biomaterials and iPSCs will be critical in the successful application of iPSCs and their progeny for research and clinical translation.

show abstract

Footprint- and xeno-free human iPSCs derived from urine cells using extracellular matrix-based culture conditions

Cited by 22 publications

References 25 publications

Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications

Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications

Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions

Application of biomaterials to advance induced pluripotent stem cell research and therapy

Contact Info

Product

Resources

About